
Neuphoria Therapeutics fell 47.3% from $4.46 to $2.35, behind the S&P 500's +4.7%. Its worst day was Jul 1 (−18.8%), and its low came Nov 17 at $2.27.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Neuphoria Therapeutics shares fell 8.5%, while the S&P 500 rose 0.7%.
−8.5% · S&P 500 +0.7%
EPS of $-0.77 missed the $-0.56 estimate on $0.00 revenue.
+8.9% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.09 beat the $-0.56 estimate on $0.00 revenue.
−7.3% · S&P 500 −1.2%
Neuphoria Therapeutics shares fell 18.8%, while the S&P 500 fell 0.1%.
−18.8%, the year's worst day · S&P 500 −0.1%
Neuphoria Therapeutics shares rose 17.7%, while the S&P 500 fell 1.2%.
+17.7%, the year's best day, on 8M shares, the year's heaviest volume · S&P 500 −1.2%
EPS of $-0.95 missed the $-0.56 estimate on $1.2M revenue.
+0.3% · S&P 500 +1.6%
Neuphoria Therapeutics shares fell 8.9%, while the S&P 500 fell 0.4%.
−8.9% · S&P 500 −0.4%
EPS of $-0.26 beat the $-0.42 estimate on $0.00 revenue.
−8.5% · S&P 500 −1.0%
Where it ended: a close of $2.35 on Nov 20, 2026. Up next: Q2 2027 earnings on Feb 16, 2027.
Nothing in the past 12 months.
All NEUP dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NEUP and SPY from Benzinga historical bars. Not investment advice.